Evalute the Therapy Article below and Answer Questions about it
Description
Unformatted Attachment Preview
journal of medicine
The
established in 1812
October 5, 2017
vol. 377
no. 14
Rivaroxaban with or without Aspirin in Stable
Cardiovascular Disease
J.W. Eikelboom, S.J. Connolly, J. Bosch, G.R. Dagenais, R.G. Hart, O. Shestakovska, R. Diaz, M. Alings, E.M. Lonn,
S.S. Anand, P. Widimsky, M. Hori, A. Avezum, L.S. Piegas, K.R.H. Branch, J. Probstfield, D.L. Bhatt, J. Zhu, Y. Liang,
A.P. Maggioni, P. Lopez?Jaramillo, M. O/nnell, A.K. Kakkar, K.A.A. Fox, A.N. Parkhomenko, G. Ertl, S. Stì
M. Keltai, L. Ryden, N. Pogosova, A.L. Dans, F. Lanas, P.J. Commerford, C. Torp?Pedersen, T.J. Guzik,
P.B. Verhamme, D. Vinereanu, J.-H. Kim, A.M. Tonkin, B.S. Lewis, C. Felix, K. Yusoff, P.G. Steg, K.P. Metsarinne,
N. Cook Bruns, F. Misselwitz, E. Chen, D. Leong, and S. Yusuf, for the COMPASS Investigators*??
a bs t r ac t
BACKGROUND
We evaluated whether rivaroxaban alone or in combination with aspirin would be more
effective than aspirin alone for secondary cardiovascular prevention.
METHODS
In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg
once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after
a mean follow-up of 23 months.
RESULTS
The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group
than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard
ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P
Purchase answer to see full
attachment
Have a similar assignment? "Place an order for your assignment and have exceptional work written by our team of experts, guaranteeing you A results."